Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Gastroenterology Reports
Erschienen in: Current Gastroenterology Reports 12/2016

01.12.2016 | Inflammatory Bowel Disease (S Hanauer, Section Editor)

Complementary Therapies in Inflammatory Bowel Diseases

verfasst von: Henit Yanai, Nir Salomon, Adi Lahat

Erschienen in: Current Gastroenterology Reports | Ausgabe 12/2016

Einloggen, um Zugang zu erhalten

Abstract

Inflammatory bowel diseases (IBDs) often take a chronic debilitating course. Given the chronicity of IBD, the limitations of the available medications, their potential side effects, and the impact of the disease on patients’ quality of life, it is not surprising IBD patients are ranked among the highest users of complementary and alternative medicine (CAM). Since CAM has become very popular in real-life practice of Western Communities, caregivers must gain more knowledge about these therapies, their mechanism of action, benefits, and risks. This article reviews and discusses up-to-date scientific and clinical data regarding the most prevalent herbal CAM therapies.
Literatur
1.
Sirois FM. Health-related self-perceptions over time and provider-based complementary and alternative medicine (CAM) use in people with inflammatory bowel disease or arthritis. Complement Ther Med. 2014;22(4):701–9.CrossRefPubMed
2.
Opheim R et al. Complementary and alternative medicine in patients with inflammatory bowel disease: the results of a population-based inception cohort study (IBSEN). J Crohns Colitis. 2012;6(3):345–53.CrossRefPubMed
3.
Opheim R et al. Use of complementary and alternative medicine in patients with inflammatory bowel disease: results of a cross-sectional study in Norway. Scand J Gastroenterol. 2012;47(12):1436–47.CrossRefPubMed
4.
Koning M et al. Use and predictors of oral complementary and alternative medicine by patients with inflammatory bowel disease: a population-based, case-control study. Inflamm Bowel Dis. 2013;19(4):767–78.CrossRefPubMed
5.
Langhorst J et al. Amount of systemic steroid medication is a strong predictor for the use of complementary and alternative medicine in patients with inflammatory bowel disease: results from a German national survey. Inflamm Bowel Dis. 2005;11(3):287–95.CrossRefPubMed
6.
Keefer L, Keshavarzian A. Feasibility and acceptability of gut-directed hypnosis on inflammatory bowel disease: a brief communication. Int J Clin Exp Hypn. 2007;55(4):457–66.CrossRefPubMed
7.
Deter HC et al. Psychological treatment may reduce the need for healthcare in patients with Crohn’s disease. Inflamm Bowel Dis. 2007;13(6):745–52.CrossRefPubMed
8.
Berrill JW et al. Mindfulness-based therapy for inflammatory bowel disease patients with functional abdominal symptoms or high perceived stress levels. J Crohns Colitis. 2014;8(9):945–55.CrossRefPubMed
9.
Ji J et al. Acupuncture and moxibustion for inflammatory bowel diseases: a systematic review and meta-analysis of randomized controlled trials. Evid Based Complement Alternat Med. 2013;2013:158352.CrossRefPubMedPubMedCentral
10.
Fabricant DS, Farnsworth NR. The value of plants used in traditional medicine for drug discovery. Environ Health Perspect. 2001;109 Suppl 1:69–75.CrossRefPubMedPubMedCentral
11.
Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther. 1997;74(2):129–80.CrossRefPubMed
12.
Izzo AA et al. The role of cannabinoid receptors in intestinal motility, defaecation and diarrhoea in rats. Eur J Pharmacol. 1999;384(1):37–42.CrossRefPubMed
13.
14.
Shook JE, Burks TF. Psychoactive cannabinoids reduce gastrointestinal propulsion and motility in rodents. J Pharmacol Exp Ther. 1989;249(2):444–9.PubMed
15.
16.
Stander S et al. Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. J Dermatol Sci. 2005;38(3):177–88.CrossRefPubMed
17.
Heinemann A, Shahbazian A, Holzer P. Cannabinoid inhibition of guinea-pig intestinal peristalsis via inhibition of excitatory and activation of inhibitory neural pathways. Neuropharmacology. 1999;38(9):1289–97.CrossRefPubMed
18.
19.
Krowicki ZK et al. Delta9-tetrahydrocannabinol inhibits gastric motility in the rat through cannabinoid CB1 receptors. Eur J Pharmacol. 1999;371(2-3):187–96.CrossRefPubMed
20.
Coruzzi G et al. Inhibitory effect of the cannabinoid receptor agonist WIN 55,212-2 on pentagastrin-induced gastric acid secretion in the anaesthetized rat. Naunyn Schmiedebergs Arch Pharmacol. 1999;360(6):715–8.CrossRefPubMed
21.
22.
Lehmann A et al. Cannabinoid receptor agonism inhibits transient lower esophageal sphincter relaxations and reflux in dogs. Gastroenterology. 2002;123(4):1129–34.CrossRefPubMed
23.
Partosoedarso ER et al. Cannabinoid1 receptor in the dorsal vagal complex modulates lower oesophageal sphincter relaxation in ferrets. J Physiol. 2003;550(Pt 1):149–58.CrossRefPubMedPubMedCentral
24.
Izzo AA et al. Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br J Pharmacol. 2001;134(3):563–70.CrossRefPubMedPubMedCentral
25.
Mathison R et al. Effects of cannabinoid receptor-2 activation on accelerated gastrointestinal transit in lipopolysaccharide-treated rats. Br J Pharmacol. 2004;142(8):1247–54.CrossRefPubMedPubMedCentral
26.
Kimball ES et al. Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium. Am J Physiol Gastrointest Liver Physiol. 2006;291(2):G364–71.CrossRefPubMed
27.
28.
Berry EM, Mechoulam R. Tetrahydrocannabinol and endocannabinoids in feeding and appetite. Pharmacol Ther. 2002;95(2):185–90.CrossRefPubMed
29.
Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci. 2005;8(5):585–9.CrossRefPubMed
30.
Kirkham TC. Endocannabinoids in the regulation of appetite and body weight. Behav Pharmacol. 2005;16(5-6):297–313.CrossRefPubMed
31.
Pagotto U et al. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev. 2006;27(1):73–100.CrossRefPubMed
32.
Richardson JD, Aanonsen L, Hargreaves KM. Antihyperalgesic effects of spinal cannabinoids. Eur J Pharmacol. 1998;345(2):145–53.CrossRefPubMed
33.
Sharkey KA, Pittman QJ. Central and peripheral signaling mechanisms involved in endocannabinoid regulation of feeding: a perspective on the munchies. Sci STKE. 2005;2005(277):pe15.PubMed
34.
Sanson M, Bueno L, Fioramonti J. Involvement of cannabinoid receptors in inflammatory hypersensitivity to colonic distension in rats. Neurogastroenterol Motil. 2006;18(10):949–56.CrossRefPubMed
35.
Siegling A et al. Cannabinoid CB(1) receptor upregulation in a rat model of chronic neuropathic pain. Eur J Pharmacol. 2001;415(1):R5–7.CrossRefPubMed
36.
Hillsley K et al. Activation of the cannabinoid 2 (CB2) receptor inhibits murine mesenteric afferent nerve activity. Neurogastroenterol Motil. 2007;19(9):769–77.CrossRefPubMed
37.
Kulkarni-Narla A, Brown DR. Localization of CB1-cannabinoid receptor immunoreactivity in the porcine enteric nervous system. Cell Tissue Res. 2000;302(1):73–80.CrossRefPubMed
38.
Lynn AB, Herkenham M. Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. J Pharmacol Exp Ther. 1994;268(3):1612–23.PubMed
39.
Klein TW. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol. 2005;5(5):400–11.CrossRefPubMed
40.
Klein TW et al. The cannabinoid system and immune modulation. J Leukoc Biol. 2003;74(4):486–96.CrossRefPubMed
41.
Samson MT et al. Differential roles of CB1 and CB2 cannabinoid receptors in mast cells. J Immunol. 2003;170(10):4953–62.CrossRefPubMed
42.
Klein TW et al. Cannabinoid receptors and T helper cells. J Neuroimmunol. 2004;147(1-2):91–4.CrossRefPubMed
43.
Roth MD, Baldwin GC, Tashkin DP. Effects of delta-9-tetrahydrocannabinol on human immune function and host defense. Chem Phys Lipids. 2002;121(1-2):229–39.CrossRefPubMed
44.
Yuan M et al. Delta 9-tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells. J Neuroimmunol. 2002;133(1-2):124–31.CrossRefPubMed
45.
Chang YH, Lee ST, Lin WW. Effects of cannabinoids on LPS-stimulated inflammatory mediator release from macrophages: involvement of eicosanoids. J Cell Biochem. 2001;81(4):715–23.CrossRefPubMed
46.
Facchinetti F et al. Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with lypopolysaccharide. Glia. 2003;41(2):161–8.CrossRefPubMed
47.
Vannacci A et al. Nitric oxide modulates the inhibitory effect of cannabinoids on the immunological activation of guinea pig mast cells. Inflamm Res. 2003;52 Suppl 1:S07–8.PubMed
48.
Lal S et al. Cannabis use amongst patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2011;23(10):891–6.CrossRefPubMed
49.
Naftali T et al. Treatment of Crohn’s disease with cannabis: an observational study. Isr Med Assoc J. 2011;13(8):455–8.PubMed
50.
•Lahat A, Lang A, Ben-Horin S. Impact of cannabis treatment on the quality of life, weight and clinical disease activity in inflammatory bowel disease patients: a pilot prospective study. Digestion. 2012;85(1):1–8. Discusses the impact of cannabis treatment on quality of life of IBD patients.CrossRefPubMed
51.
•Naftali T et al. Cannabis induces a clinical response in patients with Crohn’s disease: a prospective placebo-controlled study. Clin Gastroenterol Hepatol. 2013;11(10):1276–1280.e1. Discusses the use of cannabis within Crohn’s disease patients within a placebo-based study.CrossRefPubMed
52.
•Storr M et al. Cannabis use provides symptom relief in patients with inflammatory bowel disease but is associated with worse disease prognosis in patients with Crohn’s disease. Inflamm Bowel Dis. 2014;20(3):472–80. Discusses the use of cannabis to relieve symptoms and also its effect on causing additional issues.CrossRefPubMed
53.
Mehmedic Z et al. Potency trends of delta9-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. J Forensic Sci. 2010;55(5):1209–17.CrossRefPubMed
54.
Hubbard JR, Franco SE, Onaivi ES. Marijuana: medical implications. Am Fam Physician. 1999;60(9):2583. -8, 2593.PubMed
55.
Hopfer CJ et al. A genome-wide scan for loci influencing adolescent cannabis dependence symptoms: evidence for linkage on chromosomes 3 and 9. Drug Alcohol Depend. 2007;89(1):34–41.CrossRefPubMed
56.
Degenhardt L et al. Epidemiological patterns of extra-medical drug use in the United States: evidence from the National Comorbidity Survey Replication, 2001-2003. Drug Alcohol Depend. 2007;90(2-3):210–23.CrossRefPubMedPubMedCentral
57.
Solowij N et al. Verbal learning and memory in adolescent cannabis users, alcohol users and non-users. Psychopharmacology (Berl). 2011;216(1):131–44.CrossRef
58.
Meier MH et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci U S A. 2012;109(40):E2657–64.CrossRefPubMedPubMedCentral
59.
••Volkow ND et al. Adverse health effects of marijuana use. N Engl J Med. 2014;370(23):2219–27. Covers the negative effects of marijuana use.CrossRefPubMedPubMedCentral
60.
Asbridge M, Hayden JA, Cartwright JL. Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis. BMJ. 2012;344, e536.CrossRefPubMedPubMedCentral
61.
•Kahan M et al. Prescribing smoked cannabis for chronic noncancer pain: preliminary recommendations. Can Fam Physician. 2014;60(12):1083–90. Covers the use of marijuana for non-cancer chronic pain.PubMedPubMedCentral
62.
Gupta SC, Kismali G, Aggarwal BB. Curcumin, a component of turmeric: from farm to pharmacy. Biofactors. 2013;39(1):2–13.CrossRefPubMed
63.
Dhillon N et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res. 2008;14(14):4491–9.CrossRefPubMed
64.
Youn HS et al. Inhibition of homodimerization of Toll-like receptor 4 by curcumin. Biochem Pharmacol. 2006;72(1):62–9.CrossRefPubMed
65.
66.
Midura-Kiela MT et al. Curcumin inhibits interferon-gamma signaling in colonic epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2012;302(1):G85–96.CrossRefPubMed
67.
Salh B et al. Curcumin attenuates DNB-induced murine colitis. Am J Physiol Gastrointest Liver Physiol. 2003;285(1):G235–43.CrossRefPubMed
68.
Sugimoto K et al. Curcumin prevents and ameliorates trinitrobenzene sulfonic acid-induced colitis in mice. Gastroenterology. 2002;123(6):1912–22.CrossRefPubMed
69.
Holt PR, Katz S, Kirshoff R. Curcumin therapy in inflammatory bowel disease: a pilot study. Dig Dis Sci. 2005;50(11):2191–3.CrossRefPubMed
70.
Hanai H et al. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2006;4(12):1502–6.CrossRefPubMed
71.
••Lang A et al. Curcumin in combination with mesalamine induces remission in patients with mild-to-moderate ulcerative colitis in a randomized controlled trial. Clin Gastroenterol Hepatol. 2015;13(8):1444–9.e1. A trial that discusses the use of curcumin in combination with mesalamine.CrossRefPubMed
72.
Singla V et al. Induction with NCB-02 (curcumin) enema for mild-to-moderate distal ulcerative colitis—a randomized, placebo-controlled, pilot study. J Crohns Colitis. 2014;8(3):208–14.CrossRefPubMed
73.
74.
Kanauchi O, Agata K, Fushiki T. Mechanism for the increased defecation and jejunum mucosal protein content in rats by feeding germinated barley foodstuff. Biosci Biotechnol Biochem. 1997;61(3):443–8.CrossRefPubMed
75.
Fukuda M et al. Prebiotic treatment of experimental colitis with germinated barley foodstuff: a comparison with probiotic or antibiotic treatment. Int J Mol Med. 2002;9(1):65–70.PubMed
76.
Kanauchi O et al. Butyrate from bacterial fermentation of germinated barley foodstuff preserves intestinal barrier function in experimental colitis in the rat model. J Gastroenterol Hepatol. 1999;14(9):880–8.CrossRefPubMed
77.
Araki Y et al. Effects of germinated barley foodstuff on microflora and short chain fatty acid production in dextran sulfate sodium-induced colitis in rats. Biosci Biotechnol Biochem. 2000;64(9):1794–800.CrossRefPubMed
78.
Kanauchi O et al. Germinated barley foodstuff, a prebiotic product, ameliorates inflammation of colitis through modulation of the enteric environment. J Gastroenterol. 2003;38(2):134–41.CrossRefPubMed
79.
Faghfoori Z et al. Effects of an oral supplementation of germinated barley foodstuff on serum tumour necrosis factor-alpha, interleukin-6 and -8 in patients with ulcerative colitis. Ann Clin Biochem. 2011;48(Pt 3):233–7.CrossRefPubMed
80.
Hanai H et al. Germinated barley foodstuff prolongs remission in patients with ulcerative colitis. Int J Mol Med. 2004;13(5):643–7.PubMed
81.
Kanauchi O et al. Treatment of ulcerative colitis by feeding with germinated barley foodstuff: first report of a multicenter open control trial. J Gastroenterol. 2002;37 Suppl 14:67–72.CrossRefPubMed
82.
Sandborn WJ et al. Andrographis paniculata extract (HMPL-004) for active ulcerative colitis. Am J Gastroenterol. 2013;108(1):90–8.CrossRefPubMed
83.
Tang T et al. Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis—a double-blind comparison with sustained release mesalazine. Aliment Pharmacol Ther. 2011;33(2):194–202.CrossRefPubMed
Metadaten
Titel
Complementary Therapies in Inflammatory Bowel Diseases
verfasst von
Henit Yanai
Nir Salomon
Adi Lahat
Publikationsdatum
01.12.2016
Verlag
Springer US
Erschienen in
Current Gastroenterology Reports / Ausgabe 12/2016
Print ISSN: 1522-8037
Elektronische ISSN: 1534-312X
DOI
https://doi.org/10.1007/s11894-016-0537-6

Weitere Artikel der Ausgabe 12/2016

Current Gastroenterology Reports 12/2016 Zur Ausgabe

Pancreas and Biliary Tract (O Haluzka, Section Editor)

Understanding the Mechanical forces of Self-Expandable Metal Stents in the Biliary Ducts

Nutrition and Obesity (S McClave, Section Editor)

Malnutrition and Nutritional Support in Alcoholic Liver Disease: a Review

Liver (S Cotler and E Kallwitz, Section Editors)

Acute-on-chronic Liver Failure

Small Intestine (D Sachar, Section Editor)

Non Celiac Gluten Sensitivity

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise